Shares of Allurion Technologies Inc. (NYSE: ALUR) experienced a significant surge in pre-market trading, escalating by 179.73% to reach $10.35. This dramatic increase follows the company’s unveiling of a strategic optimization plan centered on a novel clinical study.
Examining How the Allurion Program and GLP-1 Agonists Work Together
Allurion Technologies (ALUR) has declared its plan to start a clinical investigation into the synergistic effects of GLP-1 agonists and the Allurion Program. The purpose of the study is to look at how this combined strategy can help patients gain muscle mass and improve their overall body composition. This initiative addresses a critical concern within GLP-1 therapy, where previous studies have indicated a reduction in lean mass by approximately 40% as a proportion of total weight loss.
Addressing Lean Mass Reduction in Weight Loss Therapies
Conversely, prior research involving the Allurion Balloon, coupled with the Allurion Virtual Care Suite, has demonstrated promising results in maintaining, and in some instances, increasing muscle mass during weight loss. One study involving 571 participants revealed a 5.6% gain in lean body mass alongside a 14% reduction in total body weight over a four-month period.
Another study of 167 patients showcased a 15.7% weight reduction without any observed decrease in muscle mass. These findings highlight a potential solution to the unmet need for mitigating lean mass reduction and muscle wasting often associated with GLP-1 therapies.
Potential for Enhanced Metabolic Health and Obesity Care Standards
Allurion Technologies believes that combining its existing program with GLP-1 therapy could facilitate significant weight loss while simultaneously promoting muscle mass growth and enhancing overall body composition. The company expresses optimism that this combined approach could significantly augment the efficacy of GLP-1 therapies.
If the forthcoming study confirms these expectations, ALUR anticipates that this combined treatment modality could establish a new gold standard in obesity care, offering a more metabolically healthy approach to weight management.